Arena Pharmaceuticals Inc. Still Down After CEO's Sale

It says something about the short-term prospects for Arena Pharmaceuticals. And competitors, Orexigen and VIVUS, for that matter.

Jul 15, 2014 at 5:00PM

"Week-over-week prescriptions are increasing. We're very excited about that. And we expect those prescriptions to continue to increase as, yet a larger salesforce, goes into the field in the next few weeks."

-- Arena Pharmaceuticals (NASDAQ:ARNA) CEO Jack Lief on CNBC, June 11.

Lief was apparently so excited that he sold 38% of his stake in the company before the July 4 holiday. Investors are clearly not happy; Arena's shares fell last week, rebounded a little, but are still down substantially from where they were before the sale was announced.

Keep in mind that CEOs sell shares for all kinds of reasons. Earlier this year, Lief exercised options he had and sold the shares immediately for a profit of more than $180,000. Perhaps Lief plans to use the $1.3 million windfall from the current sale to buy a house. Property in San Diego isn't cheap you know.

Maybe he's just diversifying; he's ridden the Arena rollercoaster down and up and down again. Sometimes the front seat can be a little intense. And it's not like he got off the ride completely; he still owns almost $2 million worth of shares.

But if Lief thought there was a chance in the near future that Arena's shares were going to get to the highs the company saw in 2012 -- north of $11 per share -- it seems safe to assume that he wouldn't sell at $5.85. The inside knowledge of the day-to-day workings of the company says something about Arena Pharmaceuticals' short-term prospect.

Shares were sold under a 10b5-1 trading plan, so while Lief authorized the sale of the large block of shares, he didn't have any control over the exact timing of the sale. There's no reason to believe Lief thinks a large share price drop is imminent.

Neither is a large price increase
Arena Pharmaceuticals' marketing partner Eisai hasn't exactly rocked the launch that started in June 2013 with sales of just $8.4 million in the first quarter of this year. It doesn't seem like a problem with Qsymia per se since VIVUS (NASDAQ:VVUS) has equally struggled with its launch of Qsymia, registering just $9.1 million during the first quarter. We'll know for sure when Takeda launches Orexigen's (NASDAQ:OREX) Contrave later this year (assuming it gets approved).

Eisai increased its marketing muscle to 600 salespeople, but a lack of marketing isn't the real problem here. The only thing that's going to cure Arena, VIVUS, and Orexigen of their woes is time. Doctors have been burned too many times by side effects that have been revealed after obesity drugs have gone on the market, so they're rightfully a little apprehensive about prescribing the new drugs willy nilly. Over time, doctors will eventually become more comfortable with the drugs from Arena, VIVUS, and Orexigen and begin prescribing them to a wider audience.

If you're going to own the obesity drug makers, you should be taking a long-term perspective. There's clearly a large potential market, but it'll likely take years for them to reach it. And I'd suggest you follow Lief's lead and not take a large position in the companies. You can always add more when sales start to pick up.

Another opportunity to get in early
There is a product in development that will revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.

Brian Orelli and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 5:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at www.fool.com/podcasts.

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to www.fool.com/podcasts, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.

 


Compare Brokers